Abdulrazaq Al-Jazairi

Director, Clinical Trials Transformation Initiative (CTTI) Division. Clinical Pharmacy Consultant, Cardiology

Saudi Arabia

Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director, Clinical Trials Transformation Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania.
More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia.

Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added qualification.

Dr. Al-Jazairi has more than 50 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Founder of the Saudi Clinical Pharmacy Society, 2018. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 15 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is a member of the International Accreditation Commission, ASHP. Dr. Al-Jazairi enjoys training students and residents in Cardiology, Clinical Research and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC).